Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite

Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

By Gauthier Serge  

Current Medical Research and Opinion, Vol. 29, Iss. 8, 2013-08 ,pp. : 989-1000

Informa Healthcare

Access to resources Recommend Favorite

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

By Aupperle Peter M.   Koumaras Barbara   Chen Michael   Rabinowicz Adrian   Mirski Dario  

Current Medical Research and Opinion, Vol. 20, Iss. 10, 2004-10 ,pp. : 1605-1612

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy

By Sakka Paraskevi   Tsolaki Magda   Hort Jakub   Hager Klaus   Soininen Hilkka   López Pousa Secundino   Li Chunming   Schwam Elias  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3153-3165

Informa Healthcare

Access to resources Recommend Favorite

Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study

By Mets Tony   Vandewoude Maurits   Jacquy Jean   Deblander Anne   MacDonald Karen   Sloesen Anne   Abraham Ivo    

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2485-2501

Informa Healthcare

Access to resources Recommend Favorite